We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
Read MoreHide Full Article
Key Takeaways
XENE posted a Q2 loss of $1.07 per share, missing estimates and widening year over year.
Lead drug azetukalner is in multiple phase III studies for epilepsy, MDD, and BPD.
Cash reserves of $624.8M are expected to fund late-stage studies and operations into 2027.
Xenon Pharmaceuticals (XENE - Free Report) reported a loss of $1.07 per share for the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.03. The company had incurred a loss of 75 cents per share in the year-ago quarter.
In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX - Free Report) . The company did not recognize any revenues in the year-ago quarter as well.
XENE, in collaboration with Neurocrine, is currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, in a phase I study as a potential treatment for certain types of epilepsy. Xenon recently received a $7.5 million milestone payment from Neurocrine in connection with the progress of NBI-921355 into a clinical-stage study.
XENE's Q2 Results in Detail
In the second quarter, research and development (R&D) expenses increased 51% year over year to $75 million. The uptick was primarily due to increased expenses related to the company’s ongoing azetukalner late-stage studies in epilepsy and major depressive disorder (MDD), start-up costs for a phase III bipolar depression (BPD) study of azetukalner, and higher personnel expenses from a larger workforce.
General and administrative expenses totaled $19.2 million in the reported quarter, relatively flat year over year.
Year to date, XENE shares have lost 13% compared with the industry’s decline of 0.7%.
Image Source: Zacks Investment Research
Xenon had cash, cash equivalents and marketable securities worth $624.8 million as of June 30, 2025, compared with $691.1 million as of March 31, 2025. The company expects its existing cash balance to fund its current operating plans, which include the completion of the azetukalner phase III epilepsy studies and supporting late-stage clinical development of azetukalner in MDD and BPD into 2027.
XENE's Pipeline Updates
XENE’s lead pipeline candidate, azetukalner, is in late-stage studies for treating focal onset seizures (FOS). Under the phase III epilepsy program, two identical phase III studies, X-TOLE2 and X-TOLE3, are evaluating 15 mg or 25 mg doses of azetukalner, administered with food as adjunctive treatment in patients with FOS. The first top-line data readout from the X-TOLE2 study is anticipated in early 2026. The X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions.
The company is also evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study, which is currently enrolling patients.
Xenon has also initiated the first two of three planned phase III clinical studies, X-NOVA2 and X-NOVA3, evaluating azetukalner in patients with MDD and is currently screening patients.
During the second quarter of 2025, XENE initiated the first of two phase III clinical studies, X-CEED, to evaluate azetukalner in patients with BPD I and BPD II depression.
Xenon has initiated two separate early-stage studies evaluating XEN1120 and XEN1701, targeting Kv7 and Nav1.7, respectively, for a range of therapeutic indications.
Xenon Pharmaceuticals Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 24.1%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.
In the past 60 days, estimates for Alvotech’s 2025 earnings per share have increased from 17 cents to 18 cents. Earnings per share estimates for 2026 have increased from 81 cents to 83 cents during the same period. ALVO stock has declined 35.6% year to date.
Alvotech’s earnings beat estimates in each of the trailing three reported quarters, delivering an average surprise of 244.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
Key Takeaways
Xenon Pharmaceuticals (XENE - Free Report) reported a loss of $1.07 per share for the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.03. The company had incurred a loss of 75 cents per share in the year-ago quarter.
In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences (NBIX - Free Report) . The company did not recognize any revenues in the year-ago quarter as well.
XENE, in collaboration with Neurocrine, is currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, in a phase I study as a potential treatment for certain types of epilepsy. Xenon recently received a $7.5 million milestone payment from Neurocrine in connection with the progress of NBI-921355 into a clinical-stage study.
XENE's Q2 Results in Detail
In the second quarter, research and development (R&D) expenses increased 51% year over year to $75 million. The uptick was primarily due to increased expenses related to the company’s ongoing azetukalner late-stage studies in epilepsy and major depressive disorder (MDD), start-up costs for a phase III bipolar depression (BPD) study of azetukalner, and higher personnel expenses from a larger workforce.
General and administrative expenses totaled $19.2 million in the reported quarter, relatively flat year over year.
Year to date, XENE shares have lost 13% compared with the industry’s decline of 0.7%.
Image Source: Zacks Investment Research
Xenon had cash, cash equivalents and marketable securities worth $624.8 million as of June 30, 2025, compared with $691.1 million as of March 31, 2025. The company expects its existing cash balance to fund its current operating plans, which include the completion of the azetukalner phase III epilepsy studies and supporting late-stage clinical development of azetukalner in MDD and BPD into 2027.
XENE's Pipeline Updates
XENE’s lead pipeline candidate, azetukalner, is in late-stage studies for treating focal onset seizures (FOS). Under the phase III epilepsy program, two identical phase III studies, X-TOLE2 and X-TOLE3, are evaluating 15 mg or 25 mg doses of azetukalner, administered with food as adjunctive treatment in patients with FOS. The first top-line data readout from the X-TOLE2 study is anticipated in early 2026. The X-TOLE3 study is currently enrolling patients and is intended to support potential regulatory submissions for azetukalner for FOS in ex-U.S. jurisdictions.
The company is also evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III X-ACKT study, which is currently enrolling patients.
Xenon has also initiated the first two of three planned phase III clinical studies, X-NOVA2 and X-NOVA3, evaluating azetukalner in patients with MDD and is currently screening patients.
During the second quarter of 2025, XENE initiated the first of two phase III clinical studies, X-CEED, to evaluate azetukalner in patients with BPD I and BPD II depression.
Xenon has initiated two separate early-stage studies evaluating XEN1120 and XEN1701, targeting Kv7 and Nav1.7, respectively, for a range of therapeutic indications.
Xenon Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Xenon Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Xenon Pharmaceuticals Inc. Quote
XENE's Zacks Rank & Stocks to Consider
Xenon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and Alvotech (ALVO - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 24.1%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 34.85%.
In the past 60 days, estimates for Alvotech’s 2025 earnings per share have increased from 17 cents to 18 cents. Earnings per share estimates for 2026 have increased from 81 cents to 83 cents during the same period. ALVO stock has declined 35.6% year to date.
Alvotech’s earnings beat estimates in each of the trailing three reported quarters, delivering an average surprise of 244.18%.